Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

Core Insights - MeiraGTx Holdings has entered into a partnership with Eli Lilly, which could exceed $475 million in total value, providing Eli Lilly with rights to an experimental gene therapy targeting a rare inherited disorder [1] Company Summary - The deal with Eli Lilly represents a significant financial opportunity for MeiraGTx Holdings, highlighting the potential of its gene therapy in the pharmaceutical market [1] - The partnership underscores the growing interest in gene therapies for rare diseases, indicating a trend towards innovative treatment solutions within the industry [1]